Use of Bisphosphonates in Patients with Metastatic Bone Disease

James R. Berenson, Allan Lipton

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

Original languageEnglish (US)
Pages (from-to)1573-1579
Number of pages7
JournalOncology
Volume12
Issue number11
StatePublished - Dec 1 1998

Fingerprint

Bone Diseases
Diphosphonates
Osteoclasts
Bone Resorption
Neoplasm Metastasis
Osteitis Deformans
Bone and Bones
Neoplasms
Osteolysis
Reducing Agents
Hypercalcemia
Multiple Myeloma
Double-Blind Method
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Berenson, James R. ; Lipton, Allan. / Use of Bisphosphonates in Patients with Metastatic Bone Disease. In: Oncology. 1998 ; Vol. 12, No. 11. pp. 1573-1579.
@article{70ffe98ee4194d71905d9ba0a70fdd0f,
title = "Use of Bisphosphonates in Patients with Metastatic Bone Disease",
abstract = "Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.",
author = "Berenson, {James R.} and Allan Lipton",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "12",
pages = "1573--1579",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11",

}

Berenson, JR & Lipton, A 1998, 'Use of Bisphosphonates in Patients with Metastatic Bone Disease', Oncology, vol. 12, no. 11, pp. 1573-1579.

Use of Bisphosphonates in Patients with Metastatic Bone Disease. / Berenson, James R.; Lipton, Allan.

In: Oncology, Vol. 12, No. 11, 01.12.1998, p. 1573-1579.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of Bisphosphonates in Patients with Metastatic Bone Disease

AU - Berenson, James R.

AU - Lipton, Allan

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

AB - Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0031775028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031775028&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1573

EP - 1579

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11

ER -